Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

Lignende værker

• Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
  af: Kerepesi, Csaba, et al.
  Udgivet: (2020)
• Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV
  af: Gay, Cynthia L., et al.
  Udgivet: (2021)
• Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
  af: Satya Das, et al.
  Udgivet: (2019-11-01)
• Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
  af: Das, Satya, et al.
  Udgivet: (2019)
• Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
  af: Eun, Yeonghee, et al.
  Udgivet: (2019)